FINWIRES · TerminalLIVE
FINWIRES

SHA:600161

4 stories mentioning SHA:600161Updated just now

Every FINWIRES story that references SHA:600161, newest first.

Asia Markets

Chinese Shares End Mixed as Trade Surplus Widens, Sino-Japanese Tensions Flare

Chinese equities closed with mixed results on Tuesday as investors weighed an expanding trade surplus against fresh trade friction with Japan.The Shanghai Composite Index, the main gauge of Chinese stocks, closed 0.2% higher to close at 3,940.55. The Shenzhen Component Index declined 0.5% to 13,703.21.China's trade surplus expanded to $119.1 billion in August from $112.5 billion in July, higher than the consensus forecast of $118.6 billion tracked by Investing.com. Exports rose 25% year over year to $401.4 billion, matching expectations and accelerating from the 23.9% growth in July.However, gains were capped by escalating Sino-Japanese tensions. China's Ministry of Commerce has imposed provisional anti-dumping measures on imports of dichlorosilane from Japan, following a preliminary investigation that found evidence of market injury.In company news, Beijing Tiantan Biological Products (SHA:600161) obtained official licenses from the Gansu Provincial Health Commission for four plasma collection stations under its Lanzhou subsidiary. Shares of the blood products manufacturer closed 4% higher Tuesday.

Shanghai Composite^SZSESHA:600161
Asia

Beijing Tiantan Secures Permits for Four Plasma Stations; Shares Rise 4%

Beijing Tiantan Biological Products (SHA:600161) obtained official licenses from the Gansu Provincial Health Commission for four plasma collection stations under its Lanzhou subsidiary.The newly approved stations, Gaolan, Yongdeng, Gangu, and Jinta, are now permitted to begin operations, according to a Tuesday filing with the Shanghai bourse.Shares of the blood products manufacturer rose nearly 4% in recent trade.

SHA:600161
Asia

Beijing Tiantan Biological Products Gets Supplementary Approval for Blood Clotting Protein

China's drug regulator granted Beijing Tiantan Biological Products (SHA:600161) subsidiary Chengdu Rongsheng Pharmaceutical supplemental approval for its recombinant human coagulation factor VIII for injection, according to a Tuesday filing with the Shanghai bourse.The product which is a blood clotting protein, is subject to good manufacturing practice compliance, according to the filing.

SHA:600161
Asia

Tiantan Biological Products Gets Registration Certificate for Human Immunoglobulin Injection

Beijing Tiantan Biological Products (SHA:600161) received a drug registration certificate from China's National Medical Products Administration for its human immunoglobulin injection, according to a Shanghai bourse filing on Tuesday.The injection is used for the treatment of primary immunodeficiency diseases in patients aged 2 years and older, including X-linked agammaglobulinemia, common variable immunodeficiency and IgG subclass deficiency.The blood products manufacturer invested 104.5 million yuan into the research and development of the drug.

SHA:600161

Track with the FINWIRES app suite